WebRetina Group of Florida is currently involved in multiple national clinical trials of the latest medical and surgical advances in retinal disease, including: Active Trials (Closed to … WebThe researchers reviewed safety data from a previous trial (CRTH258AUS04) with the same drugs and found an increased frequency of medical problems* with brolucizumab, also known as RTH258. Researchers also found a similar frequency of medical problems during this trial, so they ended this trial early due to safety concerns.
WEI GUI, M.D. EMPLOYMENT HISTORY: Intern in Protein …
Websent). Protocol Number: CRTH258AUS04. Sponsor: Novartis. Role: Sub-Investigator 5. Title: ALTISSIMO: A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) Compared to Intravi- WebUnique Protocol ID: CRTH258AUS04 : Brief Title: Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections (MERLIN) got my back against the wall
WEI GUI, M.D. EMPLOYMENT HISTORY: Intern in Protein …
WebCRTH258AUS04 : Brief Title: Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections (MERLIN) Official Title: WebNovartis CRTH258AUS04 (Merlin) A multicenter, randomized, double-masked Phase 3a study to assess safety and efficacy of brolucizumab 6mg q4 weeks compared to aflibercept 2 mg q4 weeks in patients with neovascular age-related macular degeneration (nAMD) with persistent retinal fluid Novartis CRTH258C2301 (Raptor) WebStudy #: CRTH258AUS04 Study Title: A Multicenter, Randomized, Double-Masked Phase 3a Study to Assess Safety and Efficacy of Brolucizumab 6 mg q4 weeks Compared to Afliberecept 2 mg q4 Weeks in Patients with Neovascular Age-Related Macular Degeneration (nAMD) with Persistent Retinal Fluid (MERLIN) Sponsor: Apellis Study #: … child care safety registry